The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Official Title: A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Study ID: NCT05027139
Brief Summary: This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced \[inoperable\] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.
Detailed Description: Part 1 of the study will first evaluate the safety and tolerability and establish the recommended doses (RDs) of zanidatamab in combination with evorpacept (ALX148). Part 2 of the study will evaluate the anti-tumor activity of the combination of zanidatamab plus evorpacept (ALX148) at the RD levels in indication-specific expansion cohorts.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UC San Diego - Moores Cancer Center, La Jolla, California, United States
UCLA Department of Medicine Hematology/Oncology, Los Angeles, California, United States
UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange, California, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Astera Cancer Care, East Brunswick, New Jersey, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Vermont Medical Center, Burlington, Vermont, United States
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
University of Wisconsin - Madison, Madison, Wisconsin, United States